-
1
المؤلفون: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
المساهمون: University of Zurich
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 13
Dummer, R, Long, G V, Robert, C, Tawbi, H A, Flaherty, K T, Ascierto, P A, Nathan, P D, Rutkowski, P, Leonov, O, Dutriaux, C, Mandalà, M, Lorigan, P, Ferrucci, P F, Grob, J J, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, A, Brase, J C, Green, S, Haas, T, Masood, A, Gasal, E, Ribas, A & Schadendorf, D 2022, ' Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.21.01601Testمصطلحات موضوعية: Proto-Oncogene Proteins B-raf, Adult, Cancer Research, Skin Neoplasms, Adolescent, Pyridones, Clinical Trials and Supportive Activities, Clinical Sciences, Oncology and Carcinogenesis, Medizin, 610 Medicine & health, Pyrimidinones, Antibodies, Death Domain, Clinical Research, Neoplasms, Oximes, Antineoplastic Combined Chemotherapy Protocols, Receptors, Monoclonal, Genetics, Humans, Oncology & Carcinogenesis, Melanoma, Humanized, Cancer, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Human Genome, Imidazoles, Evaluation of treatments and therapeutic interventions, 10177 Dermatology Clinic, Second Primary, Oncology, 6.1 Pharmaceuticals, Mutation
وصف الملف: 928_Dummer_R._et_al._Randomized_Phase_III_Trial_Evaluationg_Spartalizumab_plus_Dabrafenib_and_Trametinib_for_BRAF_V600_mutant_JCO_2022.pdf - application/pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::512e67c5f66bacf61087d7e838e0dc59Test
https://www.zora.uzh.ch/id/eprint/213526Test/ -
2
المؤلفون: Mario Mandalà, Juliette Murris, Paola Queirolo, Ana Arance, Caroline Dutriaux, Helen Gogas, Gabriella Liszkay, Ralf Gutzmer, Claus Garbe, Keith T. Flaherty, Abir Tadmouri Sellier, Naoya Yamazaki, Jeanne Suissa, Ivana Krajsová, Vanna Chiarion Sileni, Caroline Robert, Reinhard Dummer, Groot Jan de Willem, Paolo A. Ascierto, Ashwin Gollerkeri, Carmen Loquai, Dirk Schadendorf
المساهمون: University of Zurich
مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business
وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/ -
3
المؤلفون: Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni
المساهمون: University of Zurich, Dummer, Reinhard
المصدر: The Lancet Oncology. 19:1315-1327
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business
وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2 -
4
المؤلفون: Caroline Robert, Jacob Schachter, Thierry Lesimple, C. Dutriaux, Dirk Schadendorf, Monique Tan, Axel Hauschild, Georgina V. Long, R. Dummer, Eduard Gasal, Mario Santinami, Kohinoor Dasgupta, James Larkin, Mario Mandalà, Andrew M. Haydon, John M. Kirkwood, Vanna Chiarion Sileni, Laurent Mortier, Victoria Atkinson, Marta Nyakas, Ruth Plummer
المساهمون: University of Zurich
مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, medicine.medical_treatment, Medizin, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, Trametinib, Imidazoles, Follow up studies, 10177 Dermatology Clinic, General Medicine, Middle Aged, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Disease-Free Survival, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Humans, Stage III melanoma, Protein Kinase Inhibitors, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, Survival Analysis, Clinical trial, Mutation, business, Follow-Up Studies
وصف الملف: 848_Dummer_R._et_al._Five-Year_Analysis_of_Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_Melanoma_NEJM_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d710d2b0f671e5dafc838391b9965d4aTest
https://www.zora.uzh.ch/id/eprint/190018Test -
5
المؤلفون: Eduard Gasal, Paul Nathan, Antoni Ribas, Neha Pakhle, Victoria Atkinson, Céleste Lebbé, Dirk Schadendorf, Mario Mandalà, Daniel Gusenleitner, Paolo A. Ascierto, Aisha Masood, Erika Richtig, Catarina D. Campbell, Reinhard Dummer, Ana Arance, Keith T. Flaherty, Hussein Abdul-Hassan Tawbi, Naoya Yamazaki, Georgina V. Long, Caroline Robert, Jan C. Brase
المساهمون: University of Zurich, Dummer, Reinhard
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Skin Neoplasms, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Biomarker (medicine), Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Mutation, Missense, 610 Medicine & health, Genetics and Molecular Biology, Pyrimidinones, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Young Adult, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Dabrafenib, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, General Biochemistry, business
وصف الملف: 870_Dummer_R._et_al._Combined_PD-1,_BRAF_and_MEK_inhibition_in_advanced_BRAF-mutant_melanoma_Nature_Medicine_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b17ee96d80a3281cdd7448c58c9110fTest
https://www.ncbi.nlm.nih.gov/pubmed/33020648Test -
6
المؤلفون: Vanna Chiarion-Sileni, M. Mandal, A. Hauschild, Bijoyesh Mookerjee, R. Ji, Jeffrey J. Legos, John M. Kirkwood, Victoria Atkinson, Jacob Schachter, James Larkin, Richard F. Kefford, Ping Zhang, Caroline Robert, Caroline Dutriaux, M. Santinami, Andrew Haydon, Dirk Schadendorf, Georgina V. Long, Thierry Lesimple, Reinhard Dummer, Laurent Mortier, Marta Nyakas, Ruth Plummer
المساهمون: University of Zurich, Long, Georgina V
المصدر: New England Journal of Medicine. 377:1813-1823
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Medizin, 2700 General Medicine, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Melanoma, Aged, 80 and over, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Combination therapy, Pyridones, 610 Medicine & health, Pyrimidinones, Young Adult, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, medicine, Humans, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, medicine.disease, Survival Analysis, Surgery, Clinical trial, 030104 developmental biology, Mutation, Neoplasm Recurrence, Local, business
وصف الملف: 720_Long_GV._et_al._Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_NEJM_2017.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20521edecf000680510735bacb9ee32Test
https://doi.org/10.1056/nejmoa1708539Test -
7
المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty
المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline
المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test -
8
المؤلفون: John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer
المساهمون: University of Zurich, Long, Georgina V
المصدر: Journal of Clinical Oncology
J Clin Oncolمصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Internationality, Skin Neoplasms, Time Factors, Medizin, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, 1306 Cancer Research, Stage (cooking), Melanoma, Trametinib, Hazard ratio, Age Factors, Imidazoles, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 2730 Oncology, Rapid Communication, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Placebo, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Sex Factors, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Correspondence, medicine, Humans, Dose-Response Relationship, Drug, business.industry, Cancer, Dabrafenib, medicine.disease, Clinical trial, 030104 developmental biology, business, Follow-Up Studies
وصف الملف: 767_Hauschild_A._et_al._Longer_follow-up_confirms_relapse-free_survival_benefit_with_adjuvant_dabrafenib_plus_trametinib_in_patients_JCO_2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8Test
https://doi.org/10.5167/uzh-158265Test -
9
المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto
المساهمون: University of Zurich, Hamid, Omid
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business
وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test -
10
المؤلفون: Pascal Wolter, Dirk Schadendorf, Daniil Stroiakovski, Michael Lichinitser, Jeff Legos, Paul Nathan, Peng Sun, Kamil Drucis, Keith T. Flaherty, Boguslawa Karaszewska, Antoni Ribas, Florent Grange, Anne-Marie Martin, Shonda M Little, Reinhard Dummer, Ivana Krajsová, Laurent Mortier, Vanna Chiarion-Sileni, Wendy A. Crist, Paul Lorigan, Stephen D. Rubin, Andrzej Mackiewicz, Piotr Rutkowski, Jacob Schachter, Caroline Robert, Georgina V. Long, Axel Hauschild
المساهمون: University of Zurich, Robert, Caroline
مصطلحات موضوعية: Oncology, Male, Keratoacanthoma, Indoles, Skin Neoplasms, Medizin, Kaplan-Meier Estimate, 2700 General Medicine, chemistry.chemical_compound, Antineoplastic Combined Chemotherapy Protocols, Oximes, Vemurafenib, Melanoma, Trametinib, Aged, 80 and over, education.field_of_study, Sulfonamides, Hazard ratio, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, Intention to Treat Analysis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Pyridones, Population, 610 Medicine & health, Pyrimidinones, Young Adult, Internal medicine, medicine, Humans, education, neoplasms, Protein Kinase Inhibitors, Aged, Cobimetinib, Mitogen-Activated Protein Kinase Kinases, business.industry, Dabrafenib, medicine.disease, Survival Analysis, Surgery, chemistry, Mutation, business
وصف الملف: Robert C et al. - N Engl J Med 2014.pdf - application/pdf; Print-Electronic; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb174f02e29f4375b8bd8c23ddb74764Test
https://doi.org/10.5167/uzh-107163Test